Vol 4 No 1 Suppl. 1 (2020) - Open Stream on Covid-19 Emergency
Covid-19 Emergency Open Stream Contribution

Considerations for Treating CoronaVirus (Sars-Cov-2) Infection with Passive Immunotherapy

Abraham Karpas
formerly Assistant Director of Research, Department of Haematology, Cambridge University Clinical School, UK
Douglas Bainbridge
Emeritus Consultant in Immunology, Royal London Hospital
Stephen Ash
Associate Dean and Emeritus Professor of Infectious Diseases, AUC School of Medicine, UK
Published May 4, 2020
Keywords
  • Coronavirus,
  • Sars-cov-2,
  • covid-19,
  • immunotherapy,
  • emergency
How to Cite
Karpas, A., Bainbridge, D., & Ash, S. (2020). Considerations for Treating CoronaVirus (Sars-Cov-2) Infection with Passive Immunotherapy. Substantia, 4(1), 924. https://doi.org/10.13128/Substantia-924

Abstract

The corona viruses are transient RNA viruses; once an infected individual recovers he or she becomes virus-free and immune. One could expect that in SARS-Covid-19 also, infected individuals who recover will have developed some form of protective immunity. Very little is yet known about its development, when and for how long it might last, and though it is very likely to involve virus-neutralising antibodies, to what extent it might depend on the appearance of such antibodies. However in a recent report 10 very advanced corona patients were treated with a single 200 ml dose of plasma obtained from individuals recovered from the infection. There was impressive clinical improvement.

References

  1. Y. Hinuma, K. Nagata, M. Hanaoka, M Nakai, T Matsumoto, K I Kinoshita, S Shirakawa, I Miyoshi, Proc. Nat. Acad. Sci. USA, 1981,78, 6476-6480
  2. A. Karpas, A. Biol.Rev., 2004, 79, 911-933.
  3. Y. Hinuma, personal communication.
  4. A Karpas, F Hill, M Youle, V Cullen, J Gray, N Byron, F Hayhoe, M Tenant-Flowers, L Howard, D Gilgen, Proc. Nat. Acad. Sci. USA1988, 85, 9234-9237
  5. A Karpas, I K Hewlett, F Hill, J Gray, N Byron, D Gilgen, V Bally, J K Oates, B Gazzard, J E Epstein, Proc. Nat. Acad. Sci. USA, 1990,87, 7613-7617
  6. G. Blick, W. F. Scott, S.W. Crook, S. Buchanan, T. Garton, U. Hopkins, A. M. Vadaboncoeur, J. Doolittle, L. A. Bulcraig, P. Greiger-Zanlungo, A. Karpas, Biotherapy, 1998, 11, 7-14
  7. J. Levy, T. Youvan, M.L. Lee, Blood, 1994, 84, 2130-2135
  8. D. Vittecoq, S. Chevret, L. Morand-Joubert, F. Heshmati, F. Audat, M. Bary, T. Dusautoir, A. Bismuth, J. P. Viard, F. Barré-Sinoussi, Proc. Nat. Acad. Sci. USA,1995, 92,1195-1199
  9. D. R. Bainbridge, M. W. Lowdell, I. M. Hannet, K. W. Strauss, A. Karpas. Phil.Trans. Roy. Soc. Lond. B, 1997, 352, 763-770.
  10. F. Sahrhr, R. Ansumana.,T.A. Massaquoi, B.R.Idriss, F.R.Sesay, J.M. Lamin, S. Baker, S. Nicol, B. Conton, W. Johnson, O.T. Abiri, O. Kargbo, P. Kamara, A. Goba, J.B. Russell, S.M. Gevao. J. Infection, 2017, 74, 302-309
  11. K. Duan, B. Liu, C. Li, H. Zhang, T. Yu, J. Qu, M. Zhou, L. Chen, S. Meng, Y. Hu, C. Peng, M. Yuan, J. Huang, Z. Wang, J. Yu, X. Gao, D. Wang, X. Yu, L. Li, J. Zhang, X. Wu, B. Li,Y. Xu, W. Chen, Y. Peng, Y. Hu, L. Lin, X. Liu, S. Huang, Z. Zhou, L. Zhang, Y. Wang, Z. Zhang, K. Deng, Z. Xia, Q. Gong, W. Zhang, X. Zheng, Y. Liu, H. Yang, D.Zhou, D. Yu, J. Hou, Z. Shi, S. Chen, Z. Chen, X. Zhang, X.Yang, Proc. Nat. Acad. Sci. USA, 2020, 117 (17), 9490-9496
  12. Z. Lichtenstein, personal communication.
  13. K.K.To, O.T.Tsang, W.Leung, A.R.Tam, T.Wu, D.C.Lung, C.C.Yip, J.Cai, J.M.Chan, T.S.Chik, D.P.Lau, C.Y.Choi, L.Chen, W.Chan, K.Chan, J.D.Ip, A.C.Ng, R.W.Poon, C.Luo, V.C.Cheng, J.F.Chan, I.F.Hung, Z.Chen, H.Chen, K.Yuen, Lancet Infect. Dis., 2020, https://doi.org/10.1016/S1473-3099(20)30196-1
  14. Interestingly, a recent Italian scheme by blood transfusion services in the localities of Lombardy most severely affected by Covid-19 proposes to screen all regular normal blood donations and test for viral neutralising antibody on the grounds that most individuals in the area will have had to face the virus. Those who did not succumb will have either been unusually lucky enough to escape entirely, or will have been able to resist infection and, as asymptomatics, are probably morestrongly immune than individuals recovering from the disease. By screening and selecting plasma with proven neutralising activity it is hoped to build up a bank of hyperimmune plasma for use in emergency. Details of the scheme and the test methods are notknown to the authors.